Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3

December 06, 2023 00:19:56
Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3
COR2ED - Oncology Medical Conversation
Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3

Dec 06 2023 | 00:19:56

/

Show Notes

In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin (Associate Attending on the Myeloma Service at the Memorial Sloan Kettering Cancer Center, New York, NY, USA) discuss how they choose the best treatment regimen for patients with multiple myeloma and a high-risk cytogenetic profile. 

Firstly, they discuss the treatment options available for patients with high-risk cytogenetics in the US and in Europe. However, the key question is how to decide, for each individual, which treatment option is the best one. Dr. Mateos and Dr. Lesokhin discuss the factors they consider in these decisions in their clinical practice. Although the prior treatment is the most important consideration in the relapsed setting, the type of cytogenetic abnormality also plays a role. The experts specifically discuss treatment decisions in patients with extramedullary multiple myeloma: a difficult-to-treat population.

The speakers also discuss the future of myeloma treatment. How should trial design be adapted to better meet the needs of patients with a high-risk cytogenetic profile? What will be the role of CAR-T and bispecific antibodies in this population?

The experts conclude by summarising their key take-aways from the discussion.

Other Episodes

Episode

March 28, 2024 00:26:15
Episode Cover

Perseverance pays off – Looking beyond the obvious mutations in NSCLC

Why is it important to perform comprehensive molecular testing in non-small cell lung cancer to look beyond the obvious mutations? Which biomarker tests are...

Listen

Episode

December 06, 2023 00:32:39
Episode Cover

Neuroendocrine tumours: The role of SSA at progression - To continue or not?

In this podcast, Prof. Martyn Caplin and Dr Aman Chauhan discuss the role of somatostatin analogues (SSAs) at progression and whether to continue or...

Listen

Episode

December 06, 2023 00:26:17
Episode Cover

Breast cancer: Oral SERDs in ER+ BC. Part 3 - Rare cases & treatment challenges

In this final episode, the experts discuss two patient case studies with oral SERDs (oral selective estrogen receptor degraders) and a novel therapy for...

Listen